Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation-Reference-Cited by-同舟云学术

Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation

Published:2021 Issue:3 Volume:23 Page:653-662
ISSN:1466-8033
Container-title:CrystEngComm
language:en
Short-container-title:CrystEngComm

Author:

Jia Jun-Long¹²³⁴⁵,Dai Xia-Lin¹²³⁴⁵^ORCID,Che Hao-Jie¹²³⁴⁵,Li Meng-Ting¹²³⁴⁵,Zhuang Xiao-Mei⁶⁷⁸⁵,Lu Tong-Bu⁹¹⁰³⁴⁵^ORCID,Chen Jia-Mei¹²³⁴⁵^ORCID

Affiliation:

1. Tianjin Key Laboratory of Drug Targeting and Bioimaging

2. School of Chemistry and Chemical Engineering

3. Tianjin University of Technology

4. Tianjin 300384

5. China

6. School of Information Engineering

7. Zhongshan Polytechnic

8. Zhongshan 528400

9. Institute for New Energy Materials and Low Carbon Technologies

10. School of Materials Science and Engineering

Abstract

Three cocrystals of regorafenib were synthesized, and two of them demonstrate significantly improved solubility and tabletability without compromising physicochemical stability.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Condensed Matter Physics,General Materials Science,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/CE/D0CE01341B

Reference36 articles.

1. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

2. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer

3. The ErbB/HER family of protein-tyrosine kinases and cancer

4. A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

5. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of Regorafenib monohydrate (colorectal anticancer drug) solubility in supercritical CO2: Experimental and thermodynamic modeling;Heliyon;2024-04

2. Drug-drug salts of Naftopidil with non-steroidal anti-inflammatory drugs for potential multi-drug therapy;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2024-02

3. Development and evaluation of regorafenib loaded liquid suppository for rectal delivery: In vitro, in vivo analyses;Journal of Drug Delivery Science and Technology;2024-01

4. Recent Advances in Co-Former Screening and Formation Prediction of Multicomponent Solid Forms of Low Molecular Weight Drugs;Pharmaceutics;2023-08-22

5. Recent Patents of Pharmaceutical Co-Crystals: Product Development on Anti-Cancer Drugs and Beyond;Recent Patents on Anti-Cancer Drug Discovery;2023-08